Cryo-Cell International I... (CCEL)
| Bid | 5.2 |
| Market Cap | 44.36M |
| Revenue (ttm) | 32.1M |
| Net Income (ttm) | 128.71K |
| EPS (ttm) | 0.01 |
| PE Ratio (ttm) | 522 |
| Forward PE | -536.14 |
| Analyst | Buy |
| Ask | 5.53 |
| Volume | 7,192 |
| Avg. Volume (20D) | 15,536 |
| Open | 5.09 |
| Previous Close | 5.25 |
| Day's Range | 5.09 - 5.56 |
| 52-Week Range | 4.96 - 9.50 |
| Beta | 0.69 |
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto...
Analyst Forecast
According to 1 analyst ratings, the average rating for CCEL stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 62.84% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...